Status:
COMPLETED
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in su...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on OAD monotherapy for at least 3 months
- Body Mass Index (BMI): 24-35 kg/m\^2 inclusive
Exclusion
- SUBJECTS WITH TYPE 2 DIABETES
- Receipt of any investigational drug within three months prior to this trial
- Recurrent severe hypoglycemia as judged by the investigator
- Cardiac disease
- Use of any drug (except an OAD (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level
- Haemoglobin maximum 10 g/L
- HbA1c above 12%
- Loss of more than 400 mL blood during the 3 months prior to trial start
- HEALTHY SUBJECTS
- Receipt of any investigational drug within 3 months prior to this trial
- Clinically relevant cardiac disease or any clinically significant abnormal ECG (electrocardiogram)
- Use of any drug that in the investigator's opinion could interfere with the blood glucose level
- Haemoglobin max. 10 g/L
- HbA1c at least 6%
Key Trial Info
Start Date :
February 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2001
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01511185
Start Date
February 1 2001
End Date
October 1 2001
Last Update
January 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Ann Arbor, Michigan, United States, 48109-0926